Literature DB >> 10611196

Evaluation of the relative cost-effectiveness of treatments for infertility in the UK.

Z Philips1, M Barraza-Llorens, J Posnett.   

Abstract

This paper aims to complement existing clinical guidelines by providing evidence of the relative cost-effectiveness of treatments for infertility in the UK. A series of decision-analytical models have been developed to reflect current diagnostic and treatment pathways for the five main causes of infertility. Data to populate the models are derived from a systematic review and routine National Health Service activity data, and are augmented with expert opinion. Costs are derived from an analysis of extra-contractual referral tariffs and private sector data. Sensitivity analysis has been carried out to take account of the uncertainty of model parameters and to allow results to be interpreted in the light of local circumstances. Results of the modelling exercise suggest in-vitro fertilization is the most cost-effective treatment option for severe tubal factors and endometriosis, with surgery the most cost-effective in the case of mild or moderate disease. Ovulatory factors should be treated medically with the addition of laparoscopic ovarian diathermy in the presence of polycystic ovarian syndrome. For other causes, stimulated intrauterine insemination (unexplained and moderate male factor) and stimulated donor intrauterine insemination (severe male) are cost-effective.

Entities:  

Mesh:

Year:  2000        PMID: 10611196     DOI: 10.1093/humrep/15.1.95

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  9 in total

1.  Reflections on the cost-effectiveness of recombinant FSH in assisted reproduction. The clinician's perspective.

Authors:  J Balasch; P N Barri
Journal:  J Assist Reprod Genet       Date:  2001-02       Impact factor: 3.412

2.  Economic evaluation of infertility treatment for tubal disease.

Authors:  M Granberg; A Strandell; J Thorburn; S Daya; M Wikland
Journal:  J Assist Reprod Genet       Date:  2003-08       Impact factor: 3.412

3.  Stimulated intrauterine insemination (SIUI) and donor insemination (DI) as first line management for a selected subfertile population: the Manchester experience.

Authors:  S Vitthala; T A Gelbaya; H Hunter; S A Roberts; L G Nardo
Journal:  J Assist Reprod Genet       Date:  2008-10-01       Impact factor: 3.412

4.  Polycystic ovarian syndrome: an under-recognised problem?

Authors:  Sarah C Hillman; Jeremy Dale
Journal:  Br J Gen Pract       Date:  2018-05       Impact factor: 5.386

5.  The cost effectiveness of opportunistic chlamydia screening in England.

Authors:  Elisabeth J Adams; Katherine M E Turner; W John Edmunds
Journal:  Sex Transm Infect       Date:  2007-07       Impact factor: 3.519

6.  The cost effectiveness of intracyctoplasmic sperm injection (ICSI).

Authors:  Bruce Hollingsworth; Anthony Harris; Duncan Mortimer
Journal:  J Assist Reprod Genet       Date:  2007-11-16       Impact factor: 3.412

7.  Cost-effectiveness of primary offer of IVF vs. primary offer of IUI followed by IVF (for IUI failures) in couples with unexplained or mild male factor subfertility.

Authors:  Nora Pashayan; Georgios Lyratzopoulos; Raj Mathur
Journal:  BMC Health Serv Res       Date:  2006-06-23       Impact factor: 2.655

8.  Cost-effectiveness analysis of guidelines for antihypertensive care in Finland.

Authors:  Neill Booth; Antti Jula; Pasi Aronen; Minna Kaila; Timo Klaukka; Katriina Kukkonen-Harjula; Antti Reunanen; Pekka Rissanen; Harri Sintonen; Marjukka Mäkelä
Journal:  BMC Health Serv Res       Date:  2007-10-24       Impact factor: 2.655

Review 9.  Infertility and the provision of infertility medical services in developing countries.

Authors:  Willem Ombelet; Ian Cooke; Silke Dyer; Gamal Serour; Paul Devroey
Journal:  Hum Reprod Update       Date:  2008-09-26       Impact factor: 15.610

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.